California Biomedical Industry - California Healthcare Institute

More documents

Recommendations

Info

Stem cell research facilitiesThe California Institute forRegenerative Medicine (CIRM)accelerates stem cell research in thestate through grants, loans and matchingfunds. Through its major facilities fundinginitiative, CIRM has awarded $271 millionto 12 institutions: UC Santa Barbara,Stanford, USC, UCSF, UC Santa Cruz,UC Merced, UCLA, UCI, UCB, SanfordConsortium for Regenerative Medicine,and the Buck Institute for Age Research.Each recipient was required to raisemore funds through private donations.Altogether, CIRM’s investment broughtin an additional $800 million in financialcommitments and created constructionjobs throughout the state at a time whenthose jobs were very much needed.With CIRM funds allocated in 2008, fiveof the premier new stem cell researchcenters opened in 2010, and constructionis well underway on a sixth:UC Davis Institute for RegenerativeCurres. The first of the major CIRMsupportedstem cell research laboratoriesto open, the UC Davis facility is locatedon the university’s Sacramento campus.The 54,000 square feet of renovatedspace includes Northern California’slargest academic Good ManufacturingPractice (GMP) laboratory, a stateof-the-artsuite of rooms that willenable scientists to safely prepare andmanufacture cellular and gene therapiesfor clinical trials. Designed to maximizeresearch collaboration and innovation,the facility is a centralized space forresearchers from departments andprograms throughout UC Davis as wellas a shared-research facility for otherinstitutions to use. The initial phase of theproject provides space for approximately20 senior scientists and 115 otherresearchers and technicians; plannedbuild-outs will expand the facility to servemore than 200 personnel. The $62 millionfacility opened on March 10, 2010.Sue & Bill Gross Hall: A CIRM Institute.The first major stem cell center inSouthern California, and the state’sfirst such facility built from the groundup, UCI’s stem cell research centeropened on May 14, 2010. The four-story,100,000-square-foot building serves asa regional hub for stem cell researchand education. It houses the Sue & BillGross Stem Cell Research Center, dozensof lab-based and clinical researchers,a stem cell techniques course, and amaster’s program in biotechnology withan emphasis on stem cell research.Funding for the $80 million centerincluded $10 million from Sue and BillGross as well as funds from other privatedonors and the University of California.UCLA Broad Stem Cell ResearchCenter-California Institute forRegenerative Medicine Laboratory.Located on the third floor of the newTerasaki Life Sciences Building, theBSCRC provides crucial facilities forstem cell scientists and cutting-edgecore resources in about 21,000 squarefeet. Research conducted in the newspace will range from basic stem cellinvestigations to preclinical translationalscience and, finally, clinical research.Partially funded by a $20 million donationby The Eli and Edythe Broad Foundation,the new research space opened on Oct.25, 2010.Lorry I. Lokey Stem Cell ResearchBuilding. Stanford cut the ribbon onthe largest of the CIRM buildings — agleaming 200,000-square-foot, stateof-the-artfacility — on Oct. 27, 2010.The building, which serves about 550researchers, is the largest dedicated stemcell research building in the country, if notthe world. In addition to CIRM funding,the building was developed with a $75million gift from Lorry I. Lokey.Eli and Edythe Broad CIRM Centerfor Regenerative Medicine and StemCell Research at USC. The five-story,87,500-square-foot, green-certifiedbuilding is designed to house 18 principalinvestigators and their research teams.The new stem cell research center willbe a cornerstone in the biomedicalresearch corridor on the USC HealthSciences campus. Conceived in 2005,the building’s development was fundedthrough the $30 million gift from theBroad Foundation in 2006, a $27 milliongrant awarded by CIRM in 2008 andprivate donations. The building wasdedicated on Oct. 29, 2010.Sanford Consortium for RegenerativeMedicine. Among the CIRM-funded stemcell research facilities under construction,this world-class facility will enablefour of the world’s leading biomedicalresearch institutions — Salk, Scripps,UCSD and Sanford-Burnham — topursue collaborative research projects inregenerative medicine. Scheduled to becompleted in September 2011, the facilityis being developed with $43 million fromCIRM and a $30 million donation from T.Denny Sanford.92 | California Biomedical Industry 2011 Report
Executive profileDr. Ed Holmes, President andCEO of the Sanford Consortiumfor Regenerative MedicineQ: Tell me about the origins ofthe Sanford Consortium.We came into being after the bond issue(Prop. 71) was passed and CIRM wasformed….I think the four institutions(UCSD, Salk, Scripps and Burnham)and the scientists within them allworking together is really what got usstarted. And that is continued to be thefoundation of what we do.Q: We are at a dynamic time forstem cell research — especiallywith the first human trial onspinal cord injury. What excitesyou most about the researchabout to happen here?We have begun to engage a wide groupof scientists from all four institutionsand you can see the genuine excitement.We have also begun to identify threetheme areas to work in. Neurosciences,because that is an important areafor stem cell research. Also, in thearea of cancer biology we have got atremendous amount of strength, and incardiovascular disease.But what we have discovered is thereiss so much more and we do not wantto exclude people, so we will probablyconcentrate on these three areas butembrace, though special projects, otherthings that would be important to bringinto this.We are in the position to choose amongthe very best people, but, at the sametime, we envision the consortium tobe more than this building. It is thescience but it is also all four institutions.Just because you are not located in thebuilding does not mean that you arenot a part of the Sanford Consortium.So, they have come up with some cleverways to engage people who might not bein the building long-term with specialprojects.Q: A lot of this depends on theleveraging of federal funds andright now this is still up in the air,with stem cell research held up inthe courts. What concerns do youhave there?Nobody can predict what is going tohappen in Washington and obviouslyit is an up and down situation. But Iwould say the disquiet in Washingtonhas been a boon for California. Youfind people who want to come anyway,but they want to come even more now.It would be really nice if the federalgovernment gets it sorted out — andI, personally, think they will. I amoptimistic the federal government willstraighten itself out and begin to makeinvestments.Q: What are the designconsiderations for enablingcollaborative work?For collaboration to work, first you needopportunity. We have rooms intendedto reduce certain types of behaviorand encourage collaboration. We haveteam rooms so six people at a time canhook up computers. It is a smartboard,so they can write on the screen so itcaptures the image plus what theyannotate on their screen.The building calls for wide openstaircases and large open spaces thatconnect. It should allow people to morevertically circulate.Q: Did you model this buildingafter any other facilities in thecountry?The exterior was designed toacknowledge that it has to fitcontextually with the iconic structurethat is the Salk. It started with thescientists back in 2007. This is a LEEDgold building. We are using chilledbeams throughout. We are also takingadvantage of the fact that we live ina great part of the world. We face theocean here on top of the Torrey PinesMesa, which allows for some fantasticviews. We plan to build an open-airreception space and fully take advantageof the Southern California climate.California Biomedical Industry 2011 Report | 93
Page 5 and 6:
In analyzing California’s biomedi
Page 7 and 8:
scans from patients a continent awa
Page 11 and 12:
Figure 1: Distribution of employmen
Page 13 and 14:
Figure 8: California biomedical ind
Page 15 and 16:
state operations (Figure 16). For t
Page 17 and 18:
FigureFigure20.14:VentureVenturecap
Page 19 and 20:
Survey participants also rankedfede
Page 21 and 22:
State tax credits to support the gr
Page 23 and 24:
of competing products worldwide wer
Page 25 and 26:
Sacramento area shows growth and pr
Page 27 and 28:
Figure 38: California has largest c
Page 29 and 30:
OncologyCancers in California, 2010
Page 31 and 32:
Diagnostics advancementsNew ovarian
Page 33 and 34:
Patient profileBill Walton striding
Page 35 and 36:
families themselves; to institution
Page 37 and 38:
HIV and AIDS statisticsby stateAn e
Page 39 and 40:
Researcher profileDr. Samuel So add
Page 41 and 42: Immunology and inflammatory disorde
Page 43 and 44: Cardiovascular diseaseAs is the cas
Page 45 and 46: Diabetes and metabolic disordersPha
Page 47 and 48: Researcher profileFrancine R. Kaufm
Page 49 and 50: ___________________________________
Page 51 and 52: Figure 41. Since 2007 there has bee
Page 53 and 54: time that wireless technologies can
Page 55: Workforce developmentA thriving ent
Page 58 and 59: access and quality while addressing
Page 60 and 61: California State University SystemR
Page 62 and 63: StanfordSummer research program re-
Page 64 and 65: Bellush said that bringing BiotechA
Page 66 and 67: Amylin PharmaceuticalsSummer Intern
Page 68 and 69: Bringing Science to Life in OurScho
Page 70 and 71: the private sector. NIH funding ena
Page 72 and 73: Small Business Administrationprogra
Page 74 and 75: Promising UC research fundedby NIHB
Page 76 and 77: University of Southern California
Page 78 and 79: Stanford UniversitySince its foundi
Page 80 and 81: The Scripps Research Institute (TSR
Page 82 and 83: Sanford-Burnham Medical Research In
Page 85 and 86: small biotechnology companies as th
Page 87 and 88: The Salk Institute celebrates 50 ye
Page 89 and 90: Bayer HealthCare establishes U.S.In
Page 91: UC Merced: Addressing healthcare di
Page 97 and 98: “Only by lowering the barriers to
Page 99 and 100: Researcher profileHans Keirstead, P
Page 101 and 102: Special sectionPharmaceuticals in t
Page 103 and 104: MethodologyEmployment, Wages, andIn
Page 105: NIH GrantsDataData for this analysi
Page 108: Report authors hereDavid L. Gollahe
show all

California Biomedical Industry - California Healthcare Institute

Create successful ePaper yourself

Delete template?

Save as template?